Unit of Human Nutrition, Department of Food Science and Technology, Agricultural University of Athens, Iera Odos 75, Athens 11855, Greece.
Curr Vasc Pharmacol. 2013 Nov;11(6):858-79. doi: 10.2174/15701611113116660176.
The metabolic syndrome (MetS) is a cluster of metabolic conditions associated to abdominal obesity, such as elevated blood pressure, impaired glucose tolerance, insulin resistance, elevated triglycerides, and low high-density lipoprotein cholesterol concentrations. Each of the associated conditions has an independent effect, but clustering together they become synergistic, making the risk of developing cardiovascular disease (CVD) greater. There is a big debate as to whether the MetS alone or its associated health conditions are more important for CVD incidence and mortality or whether prevention and/or treatment of the MetS will reduce CVD incidence and mortality. This article reviews the evidence that demonstrates that individuals with the MetS are at increased risk for CVD incidence and mortality and discusses these debated issues.
代谢综合征(MetS)是一组与腹部肥胖相关的代谢异常,包括高血压、葡萄糖耐量受损、胰岛素抵抗、甘油三酯升高和高密度脂蛋白胆固醇浓度降低等。每种相关疾病都有独立的影响,但聚集在一起会产生协同作用,使患心血管疾病(CVD)的风险更大。目前对于代谢综合征本身或其相关健康状况对于 CVD 发病率和死亡率的影响,以及预防和/或治疗代谢综合征是否会降低 CVD 发病率和死亡率,存在很大的争议。本文综述了表明代谢综合征患者 CVD 发病率和死亡率增加的证据,并讨论了这些有争议的问题。